4.7 Article

Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease

期刊

AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 116, 期 4, 页码 723-732

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/ajg.0000000000000994

关键词

-

资金

  1. Rio Hortega grant from Instituto de Salud Carlos III, Spain
  2. PERIS intensification grant by Departament de Salut de la Generalitat de Catalonia [267/G60594009]
  3. Instituto de Salud Carlos III [PI17/00310, PI18/00947]
  4. European Union (ERDF/ESF, Investing in your future-Una manera de hacer Europa)

向作者/读者索取更多资源

This study aimed to explore the prevalence of portal hypertension in different etiologies of patients with cACLD and develop classification rules based on LSM. The prevalence of portal hypertension was high in most etiologies except for NASH patients, especially obese ones. LSM >= 25 kPa was sufficient to diagnose CSPH in most etiologies, except for obese NASH patients.
INTRODUCTION: We aimed to explore the prevalence of portal hypertension in the most common etiologies of patients with compensated advanced chronic liver disease (cACLD) and develop classification rules, based on liver stiffness measurement (LSM), that could be readily used to diagnose or exclude clinically significant portal hypertension (CSPH) in clinical practice. METHODS: This is an international cohort study including patients with paired LSM/hepatic venous pressure gradient (HVPG), LSM >= 10 kPa, and no previous decompensation. Portal hypertension was defined by an HVPG >5 mm Hg. A positive predictive value >= 90% was considered to validate LSM cutoffs for CSPH (HVPG >= 10 mm Hg), whereas a negative predictive value >= 90% ruled out CSPH. RESULTS: A total of 836 patients with hepatitis C (n = 358), nonalcoholic steatohepatitis (NASH, n = 248), alcohol use (n = 203), and hepatitis B (n = 27) were evaluated. Portal hypertension prevalence was >90% in all cACLD etiologies, except for patients with NASH (60.9%), being even lower in obese patients with NASH (53.3%); these lower prevalences of portal hypertension in patients with NASH were maintained across different strata of LSM values. LSM >= 25 kPa was the best cutoff to rule in CSPH in alcoholic liver disease, chronic hepatitis B, chronic hepatitis C, and nonobese patients with NASH, whereas in obese NASH patients, the positive predictive value was only 62.8%. A new model for patients with NASH (ANTICIPATE-NASH model) to predict CSPH considering body mass index, LSM, and platelet count was developed, and a nomogram was constructed. LSM <= 15 kPa plus platelets >= 150 x 10(9)/L ruled out CSPH in most etiologies. DISCUSSION: Patients with cACLD of NASH etiology, especially obese patients with NASH, present lower prevalences of portal hypertension compared with other cACLD etiologies. LSM >= 25 kPa is sufficient to rule in CSPH in most etiologies, including nonobese patients with NASH, but not in obese patients with NASH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据